These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18681815)

  • 1. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.
    Ofili EO; Cable G; Neutel JM; Saunders E
    J Womens Health (Larchmt); 2008; 17(6):931-8. PubMed ID: 18681815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
    Neutel JM; Saunders E; Bakris GL; Cushman WC; Ferdinand KC; Ofili EO; Sowers JR; Weber MA;
    J Clin Hypertens (Greenwich); 2005 Oct; 7(10):578-86. PubMed ID: 16227760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
    Sowers JR; Neutel JM; Saunders E; Bakris GL; Cushman WC; Ferdinand KC; Ofili EO; Weber MA;
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):470-80. PubMed ID: 16849900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.
    Ofili EO; Ferdinand KC; Saunders E; Neutel JM; Bakris GL; Cushman WC; Sowers JR; Weber MA
    J Natl Med Assoc; 2006 Apr; 98(4):618-26. PubMed ID: 16623075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
    Chrysant SG; Neutel JM; Ferdinand KC;
    J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.
    Cushman WC; Neutel JM; Saunders E; Bakris GL; Ferdinand KC; Ofili EO; Sowers JR; Madder R; Weber MA
    Am J Geriatr Cardiol; 2008; 17(1):27-36. PubMed ID: 18174757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
    Neutel JM
    Postgrad Med; 2011 Jul; 123(4):126-34. PubMed ID: 21680997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender.
    Asmar R; Oparil S
    Clin Exp Hypertens; 2010; 32(8):499-503. PubMed ID: 21091220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
    Coca A; Calvo C; Sobrino J; Gómez E; López-Paz JE; Sierra C; Bragulat E; de la Sierra A
    Clin Ther; 2003 Nov; 25(11):2849-64. PubMed ID: 14693309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
    Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
    Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.
    Neutel JM; Franklin SS; Oparil S; Bhaumik A; Ptaszynska A; Lapuerta P
    J Clin Hypertens (Greenwich); 2006 Dec; 8(12):850-7; quiz 858-9. PubMed ID: 17170610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in Oman.
    Al Balushi KA; Habib JQ; Al-Zakwani I
    Med Princ Pract; 2013; 22(3):265-9. PubMed ID: 23235349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
    Neutel JM; Franklin SS; Bhaumik A; Lapuerta P; Oparil S
    Clin Exp Hypertens; 2009 Oct; 31(7):572-84. PubMed ID: 19886855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
    Schrader J; Bramlage P; Lüders S; Thoenes M; Schirmer A; Paar DW
    Clin Drug Investig; 2007; 27(11):783-96. PubMed ID: 17914897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone.
    Rosenstock J; Rossi L; Lin CS; MacNeil D; Osbakken M
    J Clin Pharm Ther; 1998 Dec; 23(6):433-40. PubMed ID: 10048504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
    Lee HY; Hong BK; Chung WJ; Lee BK; Lee SH; Jeon DW; Ahn YK; Kim D; Park CK; Kim SH; Jung HO; Kim BO; Choi D
    Clin Ther; 2011 Aug; 33(8):1043-56. PubMed ID: 21831438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.
    Pool JL; Glazer R; Crikelair N; Levy D
    Clin Drug Investig; 2009; 29(12):791-802. PubMed ID: 19888785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.